Thermo Fisher Scientific Inc. announced a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability. Gibco? CHOvantage?
GS Cell Line Development Kit delivers high productivity, streamlined timelines and royalty-free, clinical stage licensing options to support scalable manufacturing. Global pipelines for protein therapeutics, including complex biologics and biosimilars used to treat conditions ranging from cancer to autoimmune and rare diseases, continue to expand. This growth is placing increasing pressure on manufacturers to shorten time to clinic, improve manufacturing consistency and control cost of goods without compromising quality or regulatory compliance.
At the same time, regulatory agencies are placing greater emphasis on demonstrating product quality and comparability to innovator molecules. The Gibco? CHOvantage?
GS Cell Line Development (CLD) Kit enables researchers to generate high-performing, CHO cell lines, achieving protein titers of =7 g/L in fed-batch cultures, establishing stable pools in as little as four weeks, and supporting selection of stable clones within 14 weeks, helping to streamline progression from early development to commercial manufacturing. Patent expirations are accelerating the development of lower-cost biosimilar medicines, increasing demand for reliable and scalable technologies that can help manufacturers bring these treatments to market more quickly while maintaining strict quality and regulatory standards. Integrated development platforms can help simplify complex manufacturing processes, shorten development timelines and support consistent large-scale production.
Simplified Licensing, No Clinical-Stage Royalties: Many cell line development systems require royalties or milestone payments during the clinical stage. The CHOvantage GS CLD Kit includes research-use rights with purchase, avoiding these common fees during development. Royalty-free, clinical-stage licensing options provide greater cost predictability and commercial flexibility, enabling a more seamless transition from development through full-scale production.
